{
  "ticker": "A",
  "cik": "0001090872",
  "company_name": "AGILENT TECHNOLOGIES, INC.",
  "filing_date": "2024-12-20",
  "item1_summary": " In the first quarter of fiscal year 2024, we announced a change in our operating segments to move our cell analysis business from our life sciences and applied markets segment to our diagnostics and genomics operating segment . All historical financial segment information has been recast to conform to this new presentation in our consolidated financial statements and accompanying notes .\n The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes . The life sciences and applied markets business provides application-focused solutions that enable customers to identify, quantify and analyze the physical and biological properties of substances and products . As of October 31, 2024, we employed approximately 17,900 people worldwide .\n We employed approximately 6,000 people as of October 31, 2024 in our life sciences and applied markets business . The Pharmaceutical, Biopharmaceutical, CRO& CMO Market consists of “for-profit” companies which participate across the pharmaceutical value chain in the areas of therapeutic research, discovery & development, clinical trials, manufacturing and quality assurance and quality control .\n The academic and government market plays an influential role in technology adoption and therapeutic developments for pharmaceutical and molecular diagnostics companies . A second sub-segment includes biopharmaceutical companies (\"biopharma\"), contract research organizations (\"CROs\") and contract manufacturing organizations (\"CMOs\") The market consists primarily of “not-for-profit” organizations .\n The upstream petroleum exploration and refining markets use our products to analyze natural gas, crude oil composition, perform intermediate material analysis, verify and improve refining processes and ensure the overall quality of gasoline, fuels, lubricants and other products . Drug testing and forensics laboratories use our instruments, software and workflow solutions for applications such as analyzing evidence associated with crime, screening athletes for performance enhancing drugs .\n The diagnostics and clinical market focus within our life sciences and applied markets business is to provide instruments, software, reagents, and consumables . The goal is to use this information to develop new therapeutic strategies and drugs as well as new diagnostic tests . There is also a significant food safety market involved in analyzing food for pathogen contamination, accurate verification of species type and evidence of genetically modified content .\n The company has developed a new line of instruments that can be used to identify and identify molecules . The company is developing a range of products that can also be used for other purposes . The products are designed to be used in a variety of ways to identify the molecules and process them into a form of form . The product is available in the U.S. and Canada .\n Agilent's LCMS portfolio includes instruments built around four main analyzer types . GC/MS are commonly used to separate compounds and introduce them to the MS system . We significantly expanded our mass spectrometry portfolio in recent years with a focus on improving performance, sensitivity, precision, robustness, ease of use and onboard intelligence .\n Vacuum technologies products are used to create, control, measure and test vacuum environments in life science, industrial and scientific applications where ultra-clean, high-vacuum environments are needed . Products include helium mass spectrometry and helium-sensing leak detection instruments used to identify and measure leaks in hermetic or vacuum environments .\n We offer a broad range of market specific consumables and supplies to complete customers' analytical workflows . We refurbish and resell certified pre-owned instruments to value-oriented customers who demand Agilent quality and performance at a budget conscious price . We had approximately 52,000 customers for our life sciences and applied markets business in fiscal year 2024 .\n Life sciences and applied markets channels focus on the therapeutics and human disease research customer base (pharma, biopharma, CRO, CMO and generics) Life Sciences and Applied Markets Sales, Marketing and Support. We deploy a multi-channel approach, marketing products to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors.\n Our diagnostics and genomics business includes the cell analysis, advanced manufacturing partnerships and research and development, pathology, companion diagnostics, reagent partnership, genomics and biomolecular analysis businesses . We compete on the basis of product performance, reliability, support quality, applications expertise, global channel coverage and price .\n BIOVECTRA and nucleic acid solutions businesses offer a broader range of contract and development manufacturing services to our customers . They also provide clinical-to-commercial scale production capabilities focused mainly on mRNA manufacturing . Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows . Fourth, we collaborate with a number of major pharmaceutical companies to develop new potential tissue pharmacodiagnostics .\n We employed approximately 4,600 people as of October 31, 2024 in our diagnostics and genomics business . We provide instruments, software, reagents, and consumables that enable customers to perform clinical research and routine testing . The clinical market for genomics consists of high complexity clinical labs performing patient testing, including “for-profit” reference laboratories, hospital labs, and molecular diagnostic companies .\n Pharmaceutical, Biopharmaceutical, CRO & CMO Market consists of “for-profit” companies which participate across the pharmaceutical value chain in the areas of therapeutic research, discovery & development, clinical trials, manufacturing and quality assurance and quality control . With the acquisition of BIOVECTRA, we will offer our pharmaceutical customers even more specialized manufacturing capabilities .\n We operate in several areas of clinica, including cell analysis and bulk antibodies . Our cell analysis portfolio includes cell analysis plate-based assays, flow cytometer, real-time cell analyzer, microplate reader, cell imaging system and related consumables . Our products also include companion diagnostic tests that are used to help identify patients most likely to benefit from a specific targeted therapy .\n In Flow Cytometry Reagents we provide reagents and kits directly to clinical laboratories working in routine cancer diagnostics . Companion diagnostics has a history of developing clinically relevant and validated tests, with accurate and effective scoring and interpretation guidelines, that enable successful regulatory approvals in our worldwide markets . We partner with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics .\n Cytogenetic Research Solutions and Microarrays provide microarrays for comparative genomic hybridization (“CGH”), mostly used by customers in cytogenetic laboratories . The arrays allow customers to detect genome-wide copy number alterations, with high levels of resolution (from entire chromosomal copy number changes to specific microdeletions or duplications)\n Automated Electrophoresis and Microfluidics are a separation technique for biomolecules such as proteins, peptides and nucleic acids . We offer a complete portfolio of  qPCR instruments, as well as specialty enzymes for amplifying difficult sample types . Our nucleic acid solutions business offers industry leading experience to efficiently advance our customers' oligo drug candidates .\n We had approximately 14,000 customers for our diagnostics and genomics business in fiscal year 2024 . We deploy a multi-channel approach, marketing products to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors . Quality control based on automated electrophoresis products has become essential throughout in-vitro transcription (\"IVT\") mRNA workflows, including vaccine development and therapeutics .\n The markets for diagnostics and genomics analytical products in which we compete are characterized by evolving industry standards and intense competition . In the U.S., we have manufacturing facilities in California, Colorado, Iowa, Massachusetts, Texas and Vermont . We selectively use third parties to provide some supply chain processes for manufacturing, warehousing and logistics. reduce costs and manufacturing cycle times.\n The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes . The services portfolio includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations .\n The academic and government market plays an influential role in technology adoption and therapeutic developments for pharmaceutical and molecular diagnostics companies . The natural gas and petroleum exploration and refining markets use our services, software and technical support to support quality control, environmental safety reviews, analysis of crude oil composition, and improve their refining processes and quality of products .\n Environmental industry customers include all levels of government, industrial and manufacturing sectors, engineering and consulting companies, commercial testing laboratories and colleges and universities . Our services also support drug testing and forensics laboratories that are involved with analyzing evidence associated with crime, screening athletes for performance enhancing drugs, analyzing samples for recreational drugs, detecting and identifying biological and chemical warfare agents .\n Agilent CrossLab customers had approximately 50,000 customers in fiscal year 2024 . A significant number of our customers are also customers of our life sciences and applied markets business . The service business is mostly recurring in nature and is less susceptible to market seasonality and industry cycles in comparison to our instrument businesses . Advancements in our offering of software and service solutions will help our customers more efficiently operate a digitally connected smart lab that can derive value out of data analytics and artificial intelligence .\n Our direct service delivery organization is regionally based and operating in 28 countries . We deliver our support services to customers in a variety of ways, including on-site assistance with repair or exchange of returned products . We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price . We also offer special industry-focused service bundles designed to meet the specific needs of pharmaceutical and biopharmaceutical, advanced materials, environmental and hydrocarbon processing customers .\n Agilent Order Fulfillment Organizations are managed from Santa Clara, California, with operations and services provided worldwide . As of October 31, 2024, our global infrastructure organization employed approximately 1,900 people worldwide . The following discussions of Research and Development, Backlog, Intellectual Property, Materials, Environmental, Regulatory Affairs and Human Capital Management include information common to each of our businesses .\n We believe that backlog is not a meaningful indicator of future business prospects for our business segments . We remain committed to investing significantly in research and development and have focused our development efforts on key strategic opportunities to align our business with available markets and position ourselves to capture market share . Backlog information is not material to an understanding of our business, we believe .\n Our research and development, manufacturing and distribution operations involve the use of hazardous substances . We apply strict standards for protection of the environment and occupational health and safety to sites inside and outside the U.S., even if not subject to regulation imposed by foreign governments . Climate change may impact our business by increasing operating costs due to impairments of our facilities and distribution systems .\n In 2021, we announced our goal to achieve net-zero greenhouse gas emissions by 2050 . We also aim to provide transparency on our approach to sustainability management through our annual ESG report . In Europe, the European Union has started to enforce new requirements, known as the EU In Vitro Diagnostic Regulation (“EU IVDR”), which imposes stricter requirements for the marketin .\n The EU IVDR requirements became effective starting in May 2022 . Failure to comply with these regulations could lead to a reduction in revenue associated with these customers . Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries .\n Global privacy laws, including the EU's General Data Protection Regulation, apply to our activities involving the processing of personal data, both in relation to our product and service offerings and the management of our workforce . Noncompliance could result in substantial fines or otherwise restrict our ability to operate and thereby have an adverse effect on our financial condition .\n We engage with our employees through consultation, surveys, ad-hoc feedback and reviews . We have an open-door policy where employees are encouraged and empowered to bring issues to management’s attention . We value diversity at all levels and continue to focus on extending diversity and inclusion initiatives across our entire workforce .\n Agilent is committed to creating a diverse work environment and is proud to be an equal opportunity employer . We believe in an inclusive workforce, where employees from a number of cultures and countries are engaged and encouraged to leverage their collective talents . As of October 31, 2024, approximately 38 percent of our full-time employees were female .\n The health and safety of our employees is a top priority for us . We encourage our people to stay up-to-date on current research and technology while enhancing their current skills and growing new skills to meet future needs . We also put special emphasis on training managers at all levels to effectively communicate, role model and reinforce our values and culture .\n Henrik Ancher-Jensen, 58, has served as our Senior Vice President, Agilent and President, Order Fulfillment and Supply chain since September 2013 . Bret DiMarco, 56, served as the Chief Legal Officer at Pendo.io Incorporated, a privately held company, from September 2022 to June 2024 .\n Simon May, 53, has served as our Senior Vice President, Agilent and President, Diagnostics and Genomics Group since May 2024 . Jonah Kirkwood led our Commercial Marketing and Operations teams from November 2021 to May 2023 . Simon May served as Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories (“Bio-Rad”) Simon May held various leadership roles including that of General Manager of the Digital Biology Group from January 2020 to December 2021 .\n Padraig McDonnell, 53, has served as our President and Chief Executive Officer since May 2024 . He served as Chief Commercial Officer and President, Agilent CrossLab Group from November 2021 to February 2024 . Angelica A. Reimann, 54, served as  Vice President and General Manager of the Chemistries and Supplies Division . Robert W. McMahon, 56, previously served as the Chief Financial Officer of Hologic, Inc., a medical technology company .\n Mike Zhang, 49, has served as our Senior Vice President, Agilent and President, Applied Markets Group since November 2024 . He previously held various leadership roles in manufacturing over the span of his 22 years at the company . Mike Zhang was Vice President and General Manager for the Gas Phase Separations Division from January 2020 to August 2024 .\n Our Amended and Restated Bylaws, Corporate Governance Standards and Standards of Business Conduct are available on our website at www.investor.agilent.com under “Governance” The company is able to provide free of charge electronic copies of our annual report on Form 10-K, quarterly reports on FormÂ10-Q, current reports on . Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable ."
}